AZ vaccine clot risk ‘likely no more than three per million doses’
Real-world data covering millions of recipients suggest the increased risk is ‘small’, researchers say
The rate of intracranial thrombotic events linked to AstraZeneca’s COVID-19 vaccine is likely no more than three per million doses, according to two massive UK studies.
The figures that have been calculated by the researchers are much lower compared with the TGA’s estimate of about two per 100,000 people and to findings from smaller studies.
The rare thrombotic side effects from Vaxzevria — the only COVID-19 vaccine manufactured in Australia — arguably had a substantial impact on the nation’s vaccine rollout, being relegated to use only among the elderly because of the risk of clotting adverse events.
In hindsight, some doctors and epidemiologists have argued Australia was too cautious.
